@christalpthehormonenp's hormone therapy promises, fact-checked

What did @christalpthehormonenp actually say?

The creator, a self-described hormone nurse practitioner, made the case that no single HRT delivery method is superior for everyone. Her core argument: "all modalities and all treatments work," and the right choice depends on lifestyle, which hormones need replacing, and a thorough clinical assessment. She also flagged that pellets carry "some little issues" and said she takes a "more moderate approach" with dosing than many other providers.

She described starting many patients on creams first, then escalating or switching based on response and convenience. She explicitly told viewers they do not have to start with pellets, which is a meaningful pushback against a trend in cash-pay hormone clinics that often lead with pellets as the default premium option.

Does the science back this up?

Mostly, yes. The evidence genuinely does support the idea that no single delivery route is universally best, and that individualization is the appropriate clinical standard. Where she earns credit is on the pellet caution. Where things get murky is her blanket statement that all modalities work equally.

A 2017 systematic review by Cirigliano in Menopause found that FDA-approved transdermal estradiol and oral micronized progesterone have the strongest safety and efficacy data in postmenopausal women. Pellets, by contrast, have far thinner evidence. A 2019 analysis by Pinkerton et al. in Menopause noted that subcutaneous pellets carry risks of pellet extrusion, infection, and difficult-to-reverse supraphysiologic hormone levels, particularly testosterone, because you cannot simply remove a pellet the way you can stop a patch or cream. That irreversibility issue is clinically real and she was right to name it, even vaguely.

Patches and gels have a decent evidence base for both estrogen and, to a lesser extent, testosterone. Pills (oral estrogen) carry a modestly elevated venous thromboembolism risk compared to transdermal routes, per a 2010 case-control study by Canonico et al. in Circulation, so the idea that all oral options are equivalent to transdermal is a stretch.

What did they get wrong (or right)?

The biggest problem is the phrase "all modalities and all treatments work." That is too broad to be accurate and potentially misleading to patients. It papers over real differences in safety profiles, particularly between oral estrogen and transdermal estrogen for cardiovascular and clot risk. A patient with a history of deep vein thrombosis should not be told all routes are equivalent and just pick based on lifestyle.

She also did not specify which hormones she is replacing. Testosterone replacement for women sits in a different regulatory category than estrogen or progesterone. There are no FDA-approved testosterone products for women in the United States as of 2024. Prescribing testosterone to women is done off-label, and that context matters for patient consent and informed decision-making. She did not mention this, which is a meaningful omission for a public-facing educational video.

What she got right: acknowledging pellet risks when many cash-pay hormone clinics actively downplay them, emphasizing a thorough intake assessment, and pushing back on pellets as a default first step. That is responsible clinical messaging.

What should you actually know?

If you are exploring HRT, here is what the evidence actually supports. First, delivery route is not just a lifestyle preference. It has real pharmacokinetic and safety implications. Transdermal estrogen avoids first-pass liver metabolism and carries lower clot risk than oral estrogen, per the Canonico 2010 data and supported by the 2022 NICE menopause guidelines.

Second, pellets deserve scrutiny. The inability to titrate or quickly reverse a pellet dose is a genuine clinical limitation, not a minor footnote. Supraphysiologic testosterone levels from pellets have been documented in case reports and are harder to manage than an overdose from a cream or gel you simply stop applying.

Third, any provider prescribing testosterone to women should be having an explicit conversation about the off-label nature of that treatment. If they are not, ask.

Fourth, "feeling like your younger self again" is marketing language, not a clinical outcome measure. Hormone therapy has evidence for specific symptoms: vasomotor symptoms, genitourinary syndrome, and in some cases mood and sleep. It is not a general anti-aging intervention with proven outcomes across the board.

• Ask your provider specifically about the safety profile of each route, not just convenience.
• Request the reasoning behind starting dose and how it will be monitored.
• If pellets are recommended first, ask why not a titratable option first.
• Confirm informed consent discussions include the off-label status of any testosterone product prescribed to you.